Prevention of cardiac surgery-associated acute kidney injury

Area of Science:

• Nephrology
• Cardiology
• Anesthesiology
• Critical Care Medicine

Background:

• Cardiac surgery-associated acute kidney injury (CSA-AKI) is a significant clinical challenge with numerous preventative strategies evaluated.
• Correction of hemodynamic instability is crucial, yet comparative studies on hemodynamic management strategies for kidney protection are lacking.
• Pharmacologic interventions like diuretics, vasodilators, and N-acetylcysteine have shown limited efficacy in preventing early CSA-AKI.

Framework:

• Current research often relies on underpowered studies with physiological endpoints rather than robust clinical outcomes.
• Further randomized trials are needed to evaluate specific agents such as fenoldopam and nesiritide (rhBNP).
• Evidence suggests potential benefits from off-pump surgery and avoiding aortic manipulation, though studies are observational or underpowered.

Implementation:

• Limited evidence supports preoperative fluid loading and preemptive renal replacement therapy (RRT).
• Caution is advised with potentially nephrotoxic agents in at-risk patients.
• Tranexamic acid or aminocaproic acid are preferred antifibrinolytics over aprotinin.
• Tight glycemic control may reduce kidney injury, particularly in post-cardiac surgery patients.

Implications:

• There is a critical need for high-quality clinical trials to establish effective preventative strategies for CSA-AKI.
• Current pharmacologic options for preventing early CSA-AKI are largely ineffective.
• No pharmacologic interventions have been adequately tested for preventing late CSA-AKI.
• Optimizing surgical techniques, judicious use of medications, and glycemic control represent key areas for future research and clinical practice.